CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Other disposition 10% owner disposed of 1,187,734 shares (other)
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Regulation FD disclosure
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SC 13G Stake Amended Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale See Remarks sold 4,000 shares at an average $21.42 ($85,669)
- 4 Open-market sale Chief Financial Officer sold 8,000 shares at $25.00 ($200,000)
- 4 Open-market sale See Remarks sold 19,574 shares at $25.00 ($489,350)
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Open-market sale See Remarks sold 1,079 shares at $25.00 ($26,975)
- 4 Open-market sale See Remarks sold 4,000 shares at an average $24.51 ($98,048)
- 4 Open-market sale See Remarks sold 7,468 shares at $25.16 ($187,895)
- 4 Open-market sale 10% owner sold 3,124 shares at $29.06 ($90,783)
Page 19 of 24 · 471 filings